Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

GermanyBack to Germany

Clinical trials in Hochheim Am Main – page 78

1 444 clinical trials in Hochheim Am Main, Germany across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Hochheim Am Main at a glance
1 444
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

1 444 trials in Hochheim Am Main

Open in trial search

Metastatic malignant melanoma+2

Not recruiting

Study of local treatment options for large metastases in patients with BRAF V600 mutated melanoma receiving encorafenib and binimetinib combination therapy

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Binimetinib
  • Sponsor:SRH Wald-Klinikum Gera GmbH

Cholangiocarcinoma

Not recruiting

Study of Ivosidenib, Durvalumab, and Gemcitabine/Cisplatin for Patients with Advanced Cholangiocarcinoma with IDH1 Mutation

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Cisplatin
  • Sponsor:Institut De Recherches Internationales Servier IRIS

Hereditary angioedema

Not recruiting

Study of Deucrictibant Extended-Release Tablets for Prevention of Hereditary Angioedema Attacks in Adults and Adolescents

Registered drug
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Deucrictibant
  • Sponsor:Pharvaris Netherlands B.V.

Triple negative breast cancer

Not recruiting

Study on the Effectiveness and Safety of Datopotamab Deruxtecan Compared to Chemotherapy in Adults with Advanced Triple-negative Breast Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Astrazeneca AB

Asthma

Not recruiting

Study on the Effectiveness and Safety of Benralizumab with Budesonide and Formoterol in Patients with Eosinophilic Asthma Uncontrolled by Standard Treatment

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Benralizumab
  • Sponsor:Astrazeneca AB

Hormone receptor positive HER2 negative breast cancer

Not recruiting

Study Comparing Elacestrant and Standard Endocrine Therapy for Patients with Early Breast Cancer at High Risk of Recurrence

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:Stemline Therapeutics Inc.

Mucopolysaccharidosis II

Not recruiting

Study on the Effects and Safety of JR-141 and Idursulfase for Patients with Hunter Syndrome

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years
  • Substances:Idursulfase
  • Sponsor:Jcr Pharmaceuticals Co. Ltd.

Hidradenitis

Not recruiting

Study on the Effectiveness and Safety of Brensocatib for Adults with Moderate to Severe Hidradenitis Suppurativa

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Brensocatib
  • Sponsor:Insmed Inc.

Hidradenitis

Not recruiting

Study on the Effectiveness of IC0624 for Patients with Mild to Moderate Hidradenitis Suppurativa

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Sodium bituminosulfonate dry substance
  • Sponsor:Ichthyol-Gesellschaft Cordes Hermanni & Co. GmbH & Co. KG

HIV infection

Not recruiting

Study on the Effectiveness of Cabotegravir and Rilpivirine for People with HIV-1 Who Have Not Responded Well to Oral Treatment

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Cabotegravir
  • Sponsor:Viiv Healthcare UK Limited

Hidradenitis+1

Not recruiting

Study on the Safety of INF904 for Patients with Moderate to Severe Chronic Spontaneous Urticaria or Hidradenitis Suppurativa

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:INF904
  • Sponsor:InflaRx GmbH

Type IIa hyperlipidaemia

Not recruiting

Study on the Safety and Effectiveness of Inclisiran for Children Aged 6 to Under 12 with Familial Hypercholesterolemia

Registered drug
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Inclisiran
  • Sponsor:Novartis Pharma AG

Other cities in Germany

The busiest research cities in the country

All 506 cities in Germany

Clinical research in Hochheim Am Main

What the registry says about research in the country

01 Rare Genetic Disorders

Innovative research focusing on Gaucher disease and Niemann-Pick disease, exploring new therapeutic approaches for these challenging genetic conditions. Studies aim to evaluate novel treatments for improving neurological symptoms and overall patient outcomes.

  • Gaucher Disease TYPE 3 Treatment
  • Niemann-Pick Disease Management
  • Genetic Disease Therapies

Clinical investigations evaluating venglustat and nizubaglustat's effectiveness in managing disease progression.

02 Lysosomal Storage Disorders

Research centered on treating Mucopolysaccharidosis Type II (Hunter Syndrome) and Pompe disease, with multiple studies investigating innovative enzyme replacement therapies and novel drug combinations.

  • Hunter Syndrome Treatment
  • Infantile-onset Pompe Disease
  • Late-onset Pompe Disease

Evaluation of treatments like JR-141 and cipaglucosidase alfa for improved patient outcomes.

03 Respiratory Diseases

Studies focused on preventing respiratory syncytial virus infections in older adults, with particular attention to vaccine development and immune response assessment.

  • RSV Prevention
  • Vaccine Development
  • Immune Response Studies

Investigation of revaccination strategies and long-term protection against respiratory infections.

Back to GermanyAll countries
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.